J 2024

Impact of breast cancer neoadjuvant chemotherapy on plasma and urine amino acid profile, plasma proteins and nitrogen metabolism

DASTYCH, Milan, Miloš HOLÁNEK, Jana GOTTWALDOVA, Zdenka CERMAKOVA, Alena MIKUSKOVA et. al.

Základní údaje

Originální název

Impact of breast cancer neoadjuvant chemotherapy on plasma and urine amino acid profile, plasma proteins and nitrogen metabolism

Autoři

DASTYCH, Milan (203 Česká republika, domácí), Miloš HOLÁNEK (203 Česká republika, domácí), Jana GOTTWALDOVA (203 Česká republika), Zdenka CERMAKOVA (203 Česká republika) a Alena MIKUSKOVA (203 Česká republika)

Vydání

SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, ABINGDON, INFORMA HEALTHCARE, 2024, 0036-5513

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 2.100 v roce 2022

Organizační jednotka

Lékařská fakulta

UT WoS

001256942300001

Klíčová slova anglicky

Neoadjuvant chemotherapy; breast cancer; amino acids; plasma proteins; nitrogen metabolism

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 5. 11. 2024 15:05, Mgr. Tereza Miškechová

Anotace

V originále

Neoadjuvant chemotherapy (NAC) is the preferred treatment option in locally advanced breast cancer (BC). The administration of NAC is associated with a wide range of adverse effects. This pilot observational prospective study examined the effect of NAC using anthracycline + cyclophosphamide (AC) followed by paclitaxel (PTx) on a portfolio of 22 plasma and urinary amino acids, plasma proteins (albumin, prealbumin, transferrin), and products of nitrogen metabolism (urea, creatinine, uric acid) in plasma and urine. Plasma and 24-h urine samples were obtained from ten patients with early breast cancer (N1-3 N0-2 M0), at the following time points: before the start of NAC and during the AC/PTx treatment period (a total of 8 measurements at three-weekly intervals). Amino acids were analyzed using ion exchange chromatography. There were no significant differences in the measured parameters in plasma and urine between pre-NAC and during AC- and PTx-treatment. No trend was detected. A significant difference in the portfolio of plasma and urinary amino acids was found only in the pre-treatment period compared to the control group. Levels of eight plasma amino acids (8/22) were significantly reduced and those of nine urine amino acids were increased (9/22). Nitrogenous catabolites in plasma and urine were not indicative of increased protein catabolism during the anthracycline and taxane treatment periods. A slightly positive nitrogen balance was accompanied by an average weight gain of 3.3 kg (range 0-6 kg). The AC/PTx treatment regimen did not cause significant changes in the monitored laboratory parameters.